NCT06684639View on ClinicalTrials.gov

A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2030

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

GD2-CAR-T cell

Split intravenous infusion of GD2-CAR-T cells \[dose escalating infusion of (1-100)x10\^6 GD2-CAR-T cells/kg\]

Trial Locations (1)

Unknown

RECRUITING

The General Hospital of Western Theater Command, Chengdu

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

The General Hospital of Western Theater Command

OTHER